Efficacy and Safety of Ricovir® in Maintaining Durability of Viral Response in Chronic Hepatitis B Patients Who Have Been Treated With Viread® and Have Undetectable HBV DNA in Serum

Chronic Hepatitis B Infection Clinical Trial

Official title:

Efficacy and Safety of Ricovir® in Maintaining Durability of Viral Response in Chronic Hepatitis B Patients Who Have Been Treated With Viread® and Have Undetectable HBV DNA in Serum

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05355467
• Other study ID #: Mylan-Ricovir-TW-01
• Status: Completed
• Phase: Phase 4
• Start date: August 21, 2019
• Est. completion date: July 13, 2021

Study information

• Verified date: April 2022
• Source: Mylan (Taiwan) Ltd
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a phase IV, open label, historical controlled comparative study to evaluate the efficacy and safety of Ricovir® in maintaining durability of viral response in CHB patients who have been treated with Viread® and have undetectable HBV DNA in serum by real-time polymerase chain reaction (PCR) assay.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 40
• Est. completion date: July 13, 2021
• Est. primary completion date: July 13, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 20 Years and older

Eligibility

Ricovir® Group

Inclusion Criteria:

• Male or female aged more than 20 years old;

• CHB patients who have been treated with Viread® for more than 1 year;

• Serum HBV DNA level is undetectable (not detected or <20 IU/mL) at screening;

• Informed consent must be obtained before the commencement of any screening procedures or study drugs

Exclusion Criteria:

• Patients with active HCC or other types of malignancy;

• Patients with impaired renal function (defined as eGFR ? 30 mL/min/1.73m2);

• Patients with hepatitis A (HAV), hepatitis C (HCV), hepatitis D (HDV) or human immunodeficiency virus (HIV) coinfection;

• Patients with alcohol dependence or addiction;

• Patients with autoimmune hepatitis;

• Patients with primary biliary cholangitis (PBC);

• Pregnancy, planning on getting pregnant, or breast-feeding;

• History of allergy, hypersensitivity, intolerance, or experiencing severe adverse reactions to tenofovir or any ingredient of the study drug;

• Not suitable for participating in this trial at the investigator's discretion.

Historical Control Group

Eligible individuals will be obtained from the TCVGH historical database based on matching (1:1) in terms of age (±5 years) and gender. To be eligible for the study, subjects must meet all of the following criteria:

• Male or female aged more than 20 years old;

• CHB patients who had been treated with Viread® for more than 1 year;

• Patients who had discontinued Viread® therapy for at least 24 weeks during the period from January 2014 to December 2021 and had undetectable HBV DNA (not detected or <20 IU/mL) in serum at the time of discontinuation;

• Patients who have the data of HBV DNA level 24 weeks after the time of discontinuation, with a time window of +4 weeks is allowed;

• The informed consent requirement will be waived based on the approval of IRB.

Related Conditions & MeSH terms

• Chronic Hepatitis B Infection
• Hepatitis
• Hepatitis A
• Hepatitis B
• Hepatitis B, Chronic
• Hepatitis, Chronic

Intervention

Drug:
• Tenofovir disoproxil fumarate
Ricovir® (tenofovir disoproxil fumarate 300 mg) 1 tablet daily. The overall treatment period is 24 weeks.

Other:
• Historical Data
Historical Data

Locations

Country	Name	City	State
Taiwan	Taichung Veterans General Hospital	Taichung

Sponsors (1)

Lead Sponsor	Collaborator
Mylan (Taiwan) Ltd

Country where clinical trial is conducted

Taiwan, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Assessment of the rates of virological recurrence of HBV	To assess the rates of virological recurrence of HBV at Week 24 with Ricovir® treatment.	Week 24
Secondary	Comparison of the HBV DNA levels between Ricovir® group and historical control group	To compare the HBV DNA levels at Week 24 between Ricovir® group and historical control group.	Week 24
Secondary	Comparison of the rates of virological recurrence of HBV between Ricovir® group and historical control group.	To compare the rates of virological recurrence of HBV at Week 24 between Ricovir® group and historical control group.	Week 24
Secondary	Monitoring of Safety profile for subjects in Ricovir® group	For subjects in Ricovir® group, physical examination, vital signs, HBV DNA level, and concomitant medications will be evaluated at Week 4, 12 and 24 after treatment. Hematology and clinical biochemistry will be performed every 12 weeks. Adverse events (AEs) will be monitored continuously during the study.	Up to 24 weeks